Close Menu

NEW YORK – Biomedical software company BostonGene said on Tuesday that it is collaborating with the Dana-Farber Cancer Institute's Weinstock Laboratory to research treatment response and resistance among patients with T-cell lymphomas.

Specifically, the partnership will focus on uncovering mechanisms that might cause patients' response or resistance to PI3 kinase inhibitors, including duvelisib (Verastem Oncology's Copiktra). Causes of adverse effects of duvelisib in patients with T-cell lymphomas will also be part of the collaboration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
24

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.